



HARVARD
MEDICAL SCHOOL

Earn up to 16.75 AMA PRA
Category 1 Credits™

Thrombosis and Thromboembolism

October 22–23, 2015 | Boston MA

*This special program is offered only once every 3 years.
To be assured a spot, early registration is strongly advised.*

Prevention

Evaluation

Diagnostics

Therapies

Devices

Treatment plans

Patient care

Guidance and state-of-the-art approaches to:

- Acute myocardial infarction
- Pulmonary embolism
- Lifestyle medicine recommendations for DVT
- Stroke prevention in atrial fibrillation
- New oral anticoagulants
- Idiopathic and chronic thromboembolic pulmonary hypertension
- Heparin-induced thrombocytopenia



Under the direction of Samuel Z. Goldhaber, MD and Paul M Ridker, MD, MPH

Register at **Thrombosis.HMSCME.com**



HARVARD MEDICAL SCHOOL

Dear Colleague:

Our understanding of thrombosis and thromboembolism has evolved rapidly. Advances in prevention, diagnosis, management, epidemiology, and pathophysiology will improve our clinical practice and yield more favorable patient outcomes.

Since 1987, the two-day Harvard Medical School CME course, **Thrombosis and Thromboembolism**, has been providing practical and timely education about these innovations in the field. Our upcoming 2015 curriculum promises to be the best in this program's 18-year history, with master clinicians updating and guiding us so we can integrate these changes into our daily practice.

This course provides an opportunity to quickly, efficiently, and effectively ensure we are current with the state of the art for:

- The etiology and pathophysiology of atherothrombosis
- The understanding of the link between inflammation and thrombotic illnesses
- Hypercoagulability testing
- Stroke prevention (and stroke prediction) in atrial fibrillation
- Caring for patients that have or are at risk for deep vein thrombosis and pulmonary embolism — this is a comprehensive look, from every angle
- The most exciting new predictive, diagnostic and treatment options, including genetics, personalized medicine, and lipid biology
- The nuances of prescribing dual antiplatelet therapy, including optimal duration and ways to minimize bleeding complications

The program also provides:

- Updated lipid guidelines (and the controversy surrounding them)
- FDA updates on new anticoagulant drugs and interventional devices to treat and prevent thrombosis and thromboembolism

The 2015 course offers new and returning attendees a fast-paced, intellectually invigorating learning experience and a forum in which new professional friendships will take root with faculty and colleagues who share common interests.

We have had the privilege of co-directing this course from its inception, and count ourselves among the many professionals who have been enriched by the knowledge-sharing and networking opportunities that this special program offers. We hope you will attend, and we look forward to welcoming you in person to this special Boston event.



Samuel Z. Goldhaber, MD
Course Director
Director, Thrombosis Research Group,
Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School



Paul M. Ridker, MD, MPH
Course Director
Senior Physician, Brigham and Women's Hospital
Eugene Braunwald Professor of Medicine,
Harvard Medical School

Thrombosis and Thromboembolism 2015

Who Should Attend

- Internists
- Cardiovascular specialists
- Vascular medicine specialists
- Critical care physicians
- Pulmonary physicians
- Surgeons
- Hematologists
- Obstetricians
- Oncologists
- Nurse practitioners
- Physician assistants
- Pharmacists
- Researchers

Course Description

In this course, internationally recognized faculty provide a concise, state-of-the-art overview of critical developments in the diagnosis, treatment, and prevention of thromboembolic disorders in the coronary, carotid, pulmonary, peripheral arterial, and venous systems.

This course, offered only once every 3 years, is intended for all general internists and cardiovascular, peripheral vascular, critical care, pulmonary, surgical, and hematologic specialists who are called upon to care for patients with thromboses in the venous and arterial systems. The course will be interactive with time set aside for active discussion with faculty.

Learning Objectives

By the end of this conference, participants will be able to:

- Better diagnose and treat venous and arterial thromboembolic disorders.
- Explain the current thinking behind why inflammation plays a much larger role in thrombotic disorders than previously thought and understand the biology behind this.
- Summarize the latest developments in the developing field of stroke prevention in atrial fibrillation.
- Appropriately utilize the new oral anticoagulants and devices available to treat venous and arterial thrombosis.

Reasons to Attend

You will get timely and important updates for:

- DVT/PE diagnosis, testing, parenteral and oral anticoagulants
- Genetics, thrombosis, and personalized medicine
- Atherothrombosis: etiology, pathophysiology, therapy
- Hypercoagulability: testing and management
- Management of chronic venous insufficiency
- Pharmacomechanical therapy
- Utilization of the vascular diagnostic laboratory
- Lipid management (and new guidelines)
- Dual antiplatelet therapy: dose, duration, reversibility
- Stroke prevention in atrial fibrillation
- Detecting atrial fibrillation after stroke
- Special considerations for VTE in cancer and pregnancy

Keynote Dinner Speaker

Eugene Braunwald, MD



For the past 30 years, Dr. Braunwald has served as Chairman of the TIMI Study Group. *Science Watch* listed him as the most frequently cited author in cardiology; the living Nobel Prize winners in

medicine voted Dr. Braunwald "the person who has contributed the most to cardiology in recent years."

Register today at Thrombosis.HMSCME.com

Thrombosis and Thromboembolism 2015

Thursday, October 22

6:45–7:45	Registration and Breakfast
7:45–8:00	<i>Seating</i>
8:00–8:15	Welcome and Course Objectives Samuel Z. Goldhaber, MD; Paul M Ridker, MD, MPH and Arthur Sasahara, MD
8:15–8:40	Atherothrombosis: Etiology, Pathophysiology, and Template for Therapy Peter Libby, MD
8:40–8:50	Discussion, Q&A
8:50–9:15	Inflammation and Atherothrombosis: Where Are We Going? Paul M Ridker, MD, MPH
9:15–9:25	Discussion, Q&A
9:25–9:50	Neutrophil Extracellular Traps in VTE: A Link Between Inflammation and Thrombosis Richard N. Mitchell, MD, PhD
9:50–10:00	Discussion, Q&A
10:00–10:25	Hypercoagulability: When Should We Test to Influence Management and When Is Testing Warranted Simply to Satisfy Curiosity? Jean Connors, MD
10:25–10:35	Discussion, Q&A
10:35–10:55	<i>Coffee break</i>
10:55–11:20	Diagnosis of DVT and PE: An Evidence-Based Approach to Streamline Testing Henri Bounameaux, MD
11:20–11:30	Discussion, Q&A
11:30–11:55	Parenteral and Oral Anticoagulants to Treat DVT and PE Jeff Weitz, MD
11:55–12:05	Discussion, Q&A
12:05–1:05	<i>Lunch (on your own)</i>

1:05–1:30	Post-Thrombotic Syndrome/ Chronic Venous Insufficiency: Impact on Quality of Life and Potential Prevention with Thrombolytic Therapy Suresh Vedantham, MD
1:30–1:40	Discussion, Q&A
1:40–2:05	DVT Pharmacomechanical Therapy in the Interventional Laboratory — Indications for Advanced Therapy and the Available Drugs and Devices Suresh Vedantham, MD
2:05–2:15	Discussion, Q&A
2:15–2:40	PE Pharmacomechanical Therapy: Focus on Ultrasound-Assisted Low-Dose Catheter Directed Fibrinolysis Gregory Piazza, MD, MS
2:40–2:50	Discussion, Q&A
2:50–3:15	IVC Filters: Rates of Insertion, Indications, Effects on Prognosis, Evidence Basis for Current Practices Suresh Vedantham, MD
3:15–3:25	Discussion, Q&A
3:25–3:50	PE: Pulmonary Pathophysiological and Cardiopulmonary Exercise Testing C. Gregory Elliott, MD
3:50–4:00	Discussion, Q&A
4:00–4:20	<i>Coffee break</i>
4:20–4:45	Vascular Diagnostic Laboratory: Upper and Lower Extremity DVT, including Isolated Calf DVT and Iliac Vein DVT as well as Conditions Mimicking DVT Michael Jaff, DO
4:45–4:55	Discussion, Q&A
4:55	<i>Adjourn from Fairmont Copley Plaza</i>
6:30–8:15	Keynote Dinner Lecture Eugene Braunwald, MD <i>Bornstein Auditorium, Brigham and Women's Hospital</i>

Program changes/substitutions may be made without notice.

Register today at Thrombosis.HMSCME.com

Thrombosis and Thromboembolism 2015

Friday, October 23

7:00–7:45	Breakfast	1:00–2:00	<i>Lunch (on your own)</i>
7:45–8:00	<i>Seating</i>	2:00–2:25	Devices (such as Watchman) for Stroke Prevention in Atrial Fibrillation Deepak Bhatt, MD, MPH
8:00–8:25	Genetics of Arterial and Venous Thrombosis Sekar Kathiresan, MD	2:25–2:35	Discussion, Q&A
8:25–8:35	Discussion, Q&A	2:35–3:00	Insertable Cardiac Long-Term Monitors to Detect Atrial Fibrillation after Stroke: Indications and Implications Christine M. Albert, MD, MPH
8:35–9:00	Genetics, Thrombosis, and Personalized Medicine Calum A. MacRae, MD, PhD	3:00–3:10	Discussion, Q&A
9:00–9:10	Discussion, Q&A	3:10–3:35	Chronic Thromboembolic Pulmonary Hypertension Aaron Waxman, MD
9:10–9:35	Lipid Biology and Recent Randomized Controlled Trials Paul M Ridker, MD, MPH	3:35–3:45	Discussion, Q&A
9:35–9:45	Discussion, Q&A	3:45–4:10	VTE in Cancer: Role of LMWH and Optimal Duration of Anticoagulation Craig Kessler, MD
9:45–10:10	Updated Lipid Guidelines Donna M. Polk, MD, MPH	4:10–4:20	Discussion, Q&A
10:10–10:20	Discussion, Q&A	4:20–4:45	VTE in Pregnancy: Prevention, Treatment, Role (if any) of Testing for Hypercoagulability Shannon Bates, MD
10:20–10:40	<i>Coffee break</i>	4:45–4:55	Discussion, Q&A
10:40–11:05	Antiplatelet Therapy: Understanding the Options Available when Prescribing Dual Antiplatelet Therapy: Dose, Duration, Reversibility, Bleeding Profiles Jessica L. Mega, MD, MPH	4:55–5:00	Closing Remarks
11:05–11:15	Discussion, Q&A	5:00	<i>Adjourn</i>
11:15–11:40	Dual Antiplatelet Therapy in Coronary Artery Stenting Laura Mauri, MD		
11:40–11:50	Discussion, Q&A		
11:50–12:15	Stroke Prevention in Atrial Fibrillation: Risk Stratification and Oral Anticoagulants Samuel Z. Goldhaber, MD		
12:15–12:25	Discussion, Q&A		
12:25–12:50	Stroke Prevention in Atrial Fibrillation: Biomarkers, Genetics, and Drug Levels for Dose Titration of Novel Oral Anticoagulants Christian T. Ruff, MD, MPH		
12:50–1:00	Discussion, Q&A		

Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS's policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

Register today at Thrombosis.HMSCME.com

Harvard Medical School Faculty

Christine M. Albert, MD, MPH
Associate Professor of Medicine

Deepak Bhatt, MD, MPH
Professor of Medicine

Eugene Braunwald, MD
Distinguished Hersey Professor of Medicine

Jean Connors, MD
Assistant Professor of Medicine

Samuel Z. Goldhaber, MD
Professor of Medicine

Michael Jaff, DO
Professor of Medicine

Sekar Kathiresan, MD
Associate Professor of Medicine

Peter Libby, MD
Mallinckrodt Professor of Medicine

Calum A. MacRae, MD, PhD
Associate Professor of Medicine

Laura Mauri, MD
Associate Professor of Medicine

Jessica L. Mega, MD, MPH
Associate Professor of Medicine

Richard N. Mitchell, MD, PhD
Professor of Pathology and Health Sciences and Technology

Gregory Piazza, MD, MS
Assistant Professor of Medicine

Donna M. Polk, MD, MPH
Lecturer on Medicine

Paul M Ridker, MD, MPH
Eugene Braunwald Professor of Medicine

Christian T. Ruff, MD, MPH
Assistant Professor of Medicine

Arthur Sasahara, MD
Professor of Medicine, Emeritus

Aaron Waxman, MD
Associate Professor of Medicine

Featured Guest Speakers

Shannon Bates, MD
Associate Professor of Medicine, McMaster University

Henri Bounameaux, MD
Dean of the Faculty of Medicine, University of Geneva

C. Gregory Elliott, MD
Professor of Medicine, University of Utah School of Medicine

Craig Kessler, MD
Professor of Medicine and Pathology, Georgetown University

Suresh Vedantham, MD
Professor of Radiology, Washington University

Jeff Weitz, MD
Professor of Medicine, McMaster University

Course Directors

Samuel Z. Goldhaber, MD
Professor of Medicine, Harvard Medical School
Director, Thrombosis Research Group, Brigham and Women's Hospital

Dr. Goldhaber is director of the BWH Thrombosis Research Group, medical co-director of the BWH Anticoagulation Management Service, and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism, stroke prevention in atrial fibrillation, and prevention of recurrent myocardial infarction. He has received the Certificate of Appreciation from the Surgeon General of the United States.

President and Founding Director of the nonprofit organization, North American Thrombosis Forum (www.NATFonline.org), Dr. Goldhaber has co-directed the Thrombosis and Thromboembolism course since its inception.

Paul M Ridker, MD, MPH
Eugene Braunwald Professor of Medicine, Harvard Medical School
Senior Physician, Brigham and Women's Hospital

Formally trained in cardiovascular medicine and epidemiology, Dr. Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School, and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women's Hospital in Boston. Dr. Ridker's research focuses on the design and conduct of multinational randomized trials, the development of inflammatory biomarkers for clinical and research use, the molecular and genetic epidemiology of cardiovascular diseases, and novel strategies for cardiovascular disease detection and prevention.

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of **16.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.

AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for **AMA PRA Category 1 Credits™** can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the **European Continuous Medical Education Credits (ECMEC©)** granted by the UEMS. One **AMA PRA Category 1 Credit™** is equivalent to one (1) hour of European EACCME Credit (ECMEC©), therefore up to 16.75 ECMEC© Credits are available. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

ACGME Competencies

This course is designed to meet the following Accreditation Council of Graduate Medical Education competencies: patient care, medical knowledge, and practice-based learning and improvement.

Registration Information

Register at Thrombosis.HMSCME.com

Thrombosis and Thromboembolism • October 22–23 • Boston, MA • Course #732495-1601



HARVARD
MEDICAL SCHOOL

	Register after September 20, 2015	Register on or before September 20, 2015
Physicians	\$795	\$645 (Save \$150)
Allied Health Professionals	\$695	\$545 (Save \$150)
Physicians in Training or Students	\$545	\$545

All attendees of Thrombosis and Thromboembolism will receive a flash drive containing course materials. You can purchase a printed copy of these materials at the time of registration for \$50, or on site at the course for \$90.

Registration, Payment, Confirmation and Refund Policy

Registrations for Harvard Medical School CME programs are made via our secure online registration system. To register for this course, please visit the course website. Postal, telephone, fax, and cash-payment registrations are not accepted.

At the end of the registration process you will have the choice of paying by check or credit card (VISA, MasterCard or American Express). If you are paying by check, the online registration system will provide you with instructions and a printable form for remitting your course fees by check.

Upon receipt of your paid registration, an email confirmation from the HMS DCE office will be sent to you. **Be sure to include an email address that you check frequently.** Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Refunds, less an administrative fee of \$75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by postal mail, email, or fax. No refund will be issued should cancellation occur less than two weeks prior. “No shows” are subject to the full course fee and no refunds will be issued once the conference has started.



Venue

The Fairmont Copley Plaza
138 St. James Avenue
Boston, Massachusetts
+1 617-267-5300

Accommodations

A limited number of rooms have been reserved at the Fairmont Copley Plaza Hotel in Boston, MA until September 30, 2015. When calling the hotel, please specify that you are enrolled in this activity to receive a reduced room rate. Hotel arrangements can also be made online by visiting our website at Thrombosis.HMSCME.com.

Please do not make non-refundable travel arrangements until you’ve received an email confirming your registration.

Questions? Call 617-384-8600 Monday-Friday 9am – 5pm (EST) or send email to hms-cme@hms.harvard.edu